Chemical Compound
Olmesartan Lactone Impurity
CAS Registry Number
849206-43-5
Primary Record
Olmesartan Lactone Impurity
- In stock
- 4,172 g
- Purity
- 98.5 %
- CAS
- 849206-43-5
Compound Identifiers & Properties
- CAS
- 849206-43-5
- PubChem CID
- 71751323
- SMILES
- CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC2(C)C
- Canonical SMILES
- CCCc1nc2c(n1Cc1ccc(-c3ccccc3-c3nn[nH]n3)cc1)C(=O)OC2(C)C
Names & Synonyms
- Olmesartan Lactone Impurity
- Olmesartan lactone
- 849206-43-5
- Olmesartan EP imp B
- Olmesartan EP Impurity B
- OlmesartanLactoneImpurity
- UNII-CML390S782
- RefChem:168168
- Olmesartan medoxomil related compound A
- Olmesartan Medoxomil EP Impurity B
- CML390S782
- OLM-4
- DTXSID90233966
- Olmesartan medoxomil impurity B [EP]
- orb1984409
- SCHEMBL28399163
- DTXCID20156457
- C24H24N6O2
- OLMESARTAN MEDOXOMIL IMPURITY B
- ARD182294
- ZINC77312058
- AKOS040758378
- Olmesartan lactone impurity (Standard)
- Olmesartan medoxomil related compound A [USP]
- ACN-026594
- CS-T-38010
- HY-131276R
- ID57929
- AS-88184
- DA-56429
- Olmesartan medoxomil related compound A RS [USP]
- HY-131276
- CS-0131985
- FT-0673277
- Olmesartan medoxomil related compound A (USP)
- OLMESARTAN MEDOXOMIL IMPURITY B [EP IMPURITY]
- Olmesartan Medoxomil EP Impurity B, RNH-6352
- 6,6-dimethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]furo[3,4-d]imidazol-4-one
- A900009
- F987295
- OLMESARTAN MEDOXOMIL RELATED COMPOUND A [USP-RS]
- Olmesartan medoxomil related compound A RS (USP)
- OLMESARTAN MEDOXOMIL IMPURITY B (EP IMPURITY)
- OLMESARTAN MEDOXOMIL RELATED COMPOUND A [USP IMPURITY]
- Q27275537
- 4H-Furo(3,4-d)imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
- 6,6-Dimethyl-2-propyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-3,6-dihydro-4H-furo(3,4-d)imidazol-4-one
- OLMESARTAN MEDOXOMIL RELATED COMPOUND A (USP-RS)
- yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one,
- B0176-478330
- OLMESARTAN MEDOXOMIL RELATED COMPOUND A (USP IMPURITY)
- 3,6-Dihydro-6,6-dimethyl-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-Furo[3,4-d]imidazol-4-one
- Olmesartan Lactone; 6,6-dimethyl-2-propyl-3-[[2?-(1H-tetrazol-5-yl)biphenyl-4-
- 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one
- 1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1h-furo[3,4-d]imidazol-6(4h)-one
- 4,4-dimethyl-2-propyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]furo[4,3-d]imidazol-6-one
- 6,6-Dimethyl-2- propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one
- 6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one
- 6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one; Olmesartan Medoxomil Imp. B (EP); 4H-Furo[3,4-d]imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; 4H-Furo[3,4-d]imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); 1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one; Olmesartan Medoxomil RC A (USP); Olmesartan Medoxomil Related Compound A; Olmesartan Medoxomil Impurity B
- 6,6-Dimethyl-2-propyl-3-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one
- 6,6-Dimethyl-2-propyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one